Browse articles from EyeWorld.org related to keratoconus. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Study evaluates safety of office-based lens surgery ➤ FDA issues response to BLA for 8 mg aflibercept ➤ Pre-clinical data for non-viral gene therapy ➤ Non-human primate study of dry AMD therapy ➤ Expanded insurance coverage for MIGS procedures ➤ ASCRS news and events
➤ Results from Phase 2a study evaluating glaucoma drop ➤ Enrollment complete for epi-on crosslinking trial ➤ Phase 2 clinical trial begins for investigational dry eye drop ➤ Enrollment complete for Phase 2 study to evaluate diabetic retinopathy treatment ➤ Phase 2b trial for wet AMD treatment begins enrollment ➤ ASCRS news and events
➤ ASCRS EyeWorld Weekly: View the current issue ➤ Allogenic cell therapy receives regulatory approval for bullous keratopathy indication ➤ 24-month data on AMD photobiomodulation therapy ➤ Patient enrollment complete for Phase 3 trial evaluating topical presbyopia treatment ➤ Pre-IND meeting for treatment of corneal endothelial disease ➤ IND submitted for geographic atrophy treatment ➤ Second Phase 3 trial for dry eye disease therapy ➤ ASCRS news and events
Bala Ambati, MD, won The Winning Pitch Challenge during the session at the ASCRS Annual Meeting in 2019. His company, iVeena, presented the IVMED-80, a pharmacologic drop treatment for keratoconus.
➤ Alert: eye infections linked to artificial tear ➤ Phase 2 data from research targeting Sjogren’s treatment ➤ First patient dosed in Phase 1 study for epithelial defect treatment ➤ Study compares DMEK tissue preparation techniques ➤ Topline results from oral diabetic retinopathy treatment trial ➤ ASCRS news and events
➤ NDA submitted to FDA for drug that reverses mydriasis ➤ FDA cleared IND application for gene therapy to treat form of Leber congenital amaurosis ➤ FDA approves IND for research to move forward on RP gene therapy ➤ Phase 2 study to treat geographic atrophy begins ➤ Study: Weaning patients off of AMD treatments compared ➤ Possible geographic atrophy treatment explored ➤ ASCRS news and events
➤ FDA approves new therapy for amblyopia ➤ First-in-human data from IOL/drug-delivery platform ➤ Largest crosslinking study to date for keratoconus ➤ Interim data for Phase 2 trial evaluating choroidal melanoma treatment ➤ Gene therapy update ➤ SLT trial seeking more clinical sites, deadline October 14 ➤ Acquisition news ➤ ASCRS news and events
➤ Two-year results from Phase 3 study for GA therapy ➤ BLA resubmission for bevacizumab ➤ Strategic licensing for pharmacologic treatment for keratoconus ➤ Study: Gene therapy restores some cone function to otherwise colorblind children ➤ ASCRS news and events
➤ FDA approves image and data management/analysis platform ➤ Results from pivotal Phase 3 trial for new Demodex treatment ➤ Trial demonstrates safety, efficacy of mydriasis-reversal drug in pediatric patients ➤ Phase 3 pivotal trial for novel dry eye disease, MGD drug candidate ➤ Phase 3 results for investigational geographic atrophy therapy ➤ New coalition supports sustainability in ophthalmology ➤ ASCRS news and events
➤ Roberto Zaldivar, MD, delivers the Steinert Lecture ➤ Richard Lindstrom, MD, gives Obstbaum Lecture ➤ Video cases offer a ‘Reay of Hope’ at Glaucoma Day ➤ Cornea Day covers topics in keratoconus, corneal ectasia, lamellar surgery